DoMMino-1

A Phase II, Open-Label, Multicenter Study of Inobrodib in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

More Information

Trial Status
Accepting patients
Trial Phase
Phase 2
Enrollment
100 patients (estimated)
Tags
Bromodomain Inhibitor, CBP (CREB-binding Protein) Inhibitor, P300 Inhibitor
Trial Type
Treatment
Last Update
SparkCures ID
2227
NCT Identifier
NCT07096778

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.